

GRANT AGREEMENT

This Grant Agreement ("**Agreement**") is entered into as of 15 January 2017 ("**Effective Date**") by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark ("**Novartis**") and NOPHO working group for thrombocyte diseases, represented by BørneUngeKlinikken, Rigshospitalet, SE-no.: 34 17 70 58, an Organization incorporated under the laws of Denmark, located at BørneUngeKlinikken, Juliane Marie center, Afdeling 5054, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark, ("**Grant Recipient**"). Novartis and Grant Recipient may hereinafter be referred to individually as a "**Party**" and collectively as the "**Parties**".


WHEREAS, Grant Recipient has specifically requested Novartis' financial contribution in order to support the Grant Activity (as defined in Exhibit A), through a Grant Request Letter, which is attached hereto as Exhibit B;

WHEREAS, in accordance with the Grant Request Letter mentioned above, Novartis wishes to support the Grant Activity with the Grant Amount (as defined in Exhibit A); and

WHEREAS, Grant Recipient accepts the Grant Amount subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

1. **GRANT BY NOVARTIS**
 - 1.1 **Grant.** Novartis will provide the Grant Amount as set forth in Exhibit A solely to support Grant Recipient in performing the Grant Activity as set forth in Exhibit A.
 - 1.2 **Statement of Purpose.** The Grant Activity is for scientific and/or educational purposes only and will not promote Novartis' products, directly or indirectly. The Grant Amount is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence or provide favorable formulary status for any of Novartis' products. The Grant Amount is based upon a budget provided to Novartis by Grant Recipient reflecting a good faith estimate of the actual cost of the Grant Activity. The Grant Amount has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novartis and Grant Recipient or any of their respective officers, directors, employees, agents, affiliates, parents or subsidiaries.
 - 1.3 **Novartis Responsibility.** Grant Recipient agrees that Novartis' responsibility is solely to provide the Grant Amount. Novartis will not be liable to Grant Recipient or to any other person for the Grant Activity or the use of the Grant Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Grant Recipient to return the Grant Amount and take other corrective action if Grant Recipient breaches this Agreement.



2. OBLIGATIONS OF GRANT RECIPIENT

2.1 Use of Grant Amount.


- (a) Grant Recipient shall use the Grant Amount solely for the Grant Activity and shall not use the Grant Amount for any activity that is inconsistent with, or prohibited by any law, rule or regulation. The Grant Recipient undertakes to independently contact Novartis in the event any part of the Grant Amount has not been used for the Grant Activity so that such amount can be refunded to Novartis without undue delay.
- (b) Grant Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Grant Activity. Grant Recipient warrants that the Grant Activity is compliant with all such requirements.
- (c) Grant Recipient is solely responsible for the manner in which the Grant Amount is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Grant Activity and the use of the Grant Amount. Any claims for payment from third parties involved in the Grant Activity are the sole responsibility of Grant Recipient and Novartis will not fund any additional amounts for the Grant Activity.

2.2 Objectivity & Balance.

- (a) The Grant Activity will be independent, non-promotional and free from commercial influence or bias.
- (b) If the Grant Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Grant Activity will include a discussion of multiple treatment options, and will not focus on a single product.
- (c) Grant Recipient will ensure that any titles or overview information relating to the Grant Activity will fairly and accurately represent the scope of the planned activity.
- (d) If required, Grant Recipient is responsible for selection of presenters, moderators and collaborators for the Grant Activity. Novartis will not control the planning, content, speaker selection or execution of any Grant Activity. If Novartis suggests presenters, moderators or collaborators, Grant Recipient will record the role of Novartis in making the suggestion, seek other sources and make a final selection based on balance and independence.

2.3 Disclosure of Financial Relationships.

- (a) Grant Recipient will: (i) disclose, to all audiences and in all publications relating to the Grant Activity, that Novartis has provided a grant to support the Grant Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Grant Activity; and (iii) disclose any other relationships Novartis has with any individual speakers, moderators,



collaborators or Grant Recipient which a reasonable and ethical person would expect to be disclosed.

- (b) Novartis may disclose publicly the financial and non-financial support provided to Grant Recipient, including, without limitation, the Grant Recipient's identity, the Grant Amount and purpose of the support.

2.4 Ancillary Activities.

- (a) If the Grant Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Grant Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Grant Activity.
- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Grant Activity is at the sole discretion of Grant Recipient. Meals and/or receptions, if any, will be modest and conducive to the Grant Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.
- (c) Reconciliation of Expenses. At the conclusion of the Grant Activity, Grant Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Grant Amount not incurred in the implementation of the Grant Activity. In addition, Grant Recipient will retain appropriate records of the Grant Activity and the use of the Grant Amount and will provide copies of the records to Novartis on request to confirm that the Grant Amount has been used in accordance with this Agreement.

3. GENERAL


- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.
- 3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.



NOVARTIS HEALTHCARE A/S

Signature 1 –Contract Owner


By: 

Name: ALICE MØREN

Title: MEDICAL ADVISOR

Date: 17-JAN-2017

NOPHO working group for thrombocyte diseases, represented by BørneUngeKlinikken, Rigshospitalet


By: 

Name: Mim Høsgaard

Title: MD, PhD

Date: 24. January 2017

Signature 2 –Business Approver

By: 

Name: MEDIC EISE KRÜGER HAGEN

Title: NORDIC MEDICAL DIRECTOR

Date: 20th January 2017



EXHIBIT A

GRANT AMOUNT & GRANT ACTIVITY

Grant Amount: 12.250 DKK

Grant Activity:

The grant activity will cover full day meeting packagees, including food and beverages for participants at a meeting in the NOPHO thrombocyte disease working group.

The Grant Activity does not include any entertainment activities being organized by Grant Recipient in connection with the event.

The Grant amount shall be paid by Novartis to the following bank and bank account:

Rigshospitalets SE-nr.: 34 17 70 58

Reg.nr. 3100 kontonr. 3100130815

IBAN: DK2930003100130815

Swiftkode: DABADKKK

Danske Bank

Holmens Kanal 2

1092 København K

When effectuating the payment Novartis will include the following reference: F-22716-08 / Karsten Nysom



EXHIBIT B

GRANT REQUEST LETTER

▼ You replied to this message on 24-12-2016 00:59

From: Mimi Kjærsgaard <mimi.kjaersgaard@regionh.dk> Sent: lo 24-12-2016 00:59
To: Moerch, Alice
Cc:
Subject: Ansøgning om støtte

Message: Novatis støtte ansøgning 2016.docx

Kære Alice,
Brug denne udgave, jeg fandt nogen kontooplysninger og havde glemt at skrive, I er de eneste vi spørger.

Mange hilsener

Mimi Kjærsgaard, læge
BørneUngeKlinikken, Hæmatologisk/Onkologisk afsnit,
Juliane Marie Centret
Rigshospitalet

Telefon +45 35450497

Dette e-mail indhold indeholder fortrolig information. Hvis du ikke er den rette modtager af denne e-mail, eller hvis du modtager den ved en fejlagtig e-mail, beder vi dig venligst informere afsender om fejlen ved at bruge svarfunktionen. Samtidig bedes du sætte e-mailen med det samme ud af et udsendelse eller kopiere den.

From: Mimi Kjærsgaard <mimi.kjaersgaard@regionh.dk> Sent: ma 09-01-2017 16:21
To: Moerch, Alice
Cc:
Subject: Sv: Ansøgning om støtte

Message: Novatis støtte ansøgning.docx (95 KB)

Kære Alice,
Hermed ansøgning med opdatering således dagsorden er endelig.
For nu er der 5 deltagere, som flyver ind til mødet (Finland, Norge, Aalborg). Herudover 4 som ankommer med tog fra hhv. Odense, Lund og Malmø.
Mange hilsener

Mimi Kjærsgaard, læge
BørneUngeKlinikken, Hæmatologisk/Onkologisk afsnit,
Juliane Marie Centret
Rigshospitalet

Telefon +45 35450497

(print of attachment on next page)



Mimi Kjærsgaard

Nancy Lincoln Martin, MD
Medical Advisor, Oncology
Novartis Healthcare A/S

+45 39 168440

Ansøgning om økonomisk støtte til afholdelse af fagligt møde i Nordic Society of Paediatric Haematology and Oncology (NOPHO) i arbejdsgruppen for trombocytsygdom

I NOPHO regi er også etableret samarbejde om de benigne hæmatologiske tilstande. Arbejdsgruppen for trombocytsygdomme er vores forum til diskussion af udredning og håndtering af børn med trombocytsygdomme. Samlet set drejer det sig om sjældne tilstande, og derfor er samarbejdet på tværs af Norden helt uvurderligt. Vi har f.eks. tidligere er der i gruppen gennemført en prospektiv registrering af børn med nydiagnosticeret ITP.

Formålet med denne ansøgning er økonomisk støtte, således vores kommende møde den 25. januar 2017 kan afholdes på Hilton, Kastrup Lufthavn. Baggrunden for valget af mødehotel skyldes udelukkende beliggenheden. Der deltager børnelæger fra Finland, Norge, Sverige og Danmark i dette møde. Vores mødetid bliver derfor betydelig forlænget, hvis vi har mulighed for at afholde dagen i lufthavnen.

Dagsorden

Status for udredning- og opfølgning af børn med akut og kronisk immunitrombocytopenisk purpura.
Oplæg om genetik og udredning af børn med mistænkt trombocytsygdom v. Maria Rossing, Enhed for Genomisk Medicin, Rigshospitalet, Danmark
Oplæg om thrombopoietin mimetics til børn v. Mimi Kjærsgaard, BørneUngeKlinikken, Hæmatologi/Onkologi, Rigshospitalet, Danmark
Diskussion af cases
Eventuelt og afrunding.

Hilton, Kastrup Lufthavn koster 875 kr per planlagt mødedeltager for heldagsmøde inkl. Forplejning. Typisk er vi i 2 deltager ved disse møder. Eventuel støtte kan udbetales til forskningskonto ved BørneUngeKlinikken.

Vi håber I har mulighed for at støtte os.

Med venlig hilsen

Mimi Kjærsgaard, læge, PhD

Koordinator for NOPHO trombocyt arbejdsgruppe